account_id none on file
legal_name Rigel Pharmaceuticals Inc
ticker RIGL
cik 1034842
domain rigel.com
linkedin_company_url https://www.linkedin.com/company/rigel
entry_point_account_id none on file
name Rigel Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
hq South San Francisco, CA, United States
sector index/company/sector/health-care/
calls 1 filings 60 executives 5 family 0
why_now
than 2028. after which we will begin to shift our focus to the potential launch of R289 in lower-risk MVS and other potential indications. Consistent with our prior transactions, we are prioritizing assets that leverage our existing commercial infrastructure, which will enable
Aug 4, 2026 / receipt
calls
We are expanding 40% from 39 to 55 territories, giving us the capacity to call on the majority of prescribers who treat ITP and reduce travel time for our team, allowing them to call on their customers more frequently.
Aug 3, 2021 / receipt, needs a key / Dave Santos, Chief Commercial Officer | earnings call 2021-08-03 | transcript 66b0554d-7011-4873-9086-cf7839e66fed | chars 8522-8740 | segment 8
filings
Anticipate will report positive net income for the full year 2026, while funding existing and new clinical development programs
ir_statement / Sep 17, 2026 / receipt
Interest expense (1,433) (1,853)
ir_statement / Sep 17, 2026 / receipt
Selling, general and administrative 30,651 27,715
ir_statement / Sep 17, 2026 / receipt
restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility
ir_statement / Sep 16, 2026 / receipt
Fully resourced field teams to meet customer needs in the field
ir_statement / Sep 16, 2026 / receipt
Potential for VEPPANU to become Rigel’s largest commercial product
ir_statement / Sep 16, 2026 / receipt
Successful track record of taking newly acquired assets to market quickly and efficiently
ir_statement / Sep 16, 2026 / receipt
In early May, Rigel restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility
ir_statement / Sep 16, 2026 / receipt
In mid-April, Eli Lilly notified Rigel that it will terminate the collaboration agreement
ir_statement / Sep 16, 2026 / receipt
Commercially launch VEPPANU in August
ir_statement / Sep 16, 2026 / receipt
Leverage existing commercial and operating infrastructure during integration of vepdegestrant to drive financial synergies
ir_statement / Sep 16, 2026 / receipt
In early May, Rigel restructured its credit relationship with MidCap Financial to replace its existing term loan credit facility with a revolving credit facility
ir_statement / Sep 16, 2026 / receipt
executives
| Dave Santos | Chief Commercial Officer | - | receipt |
| Keith Katkin | director | - | receipt |
| Nelson Cabatuan | Interim Principal Accounting Officer | - | receipt |
| Raul R. Rodriguez | director | - | receipt |
| Wolfgang Dummer | Chief Medical Officer | - | receipt |
familynone on file
upcoming
| 2026-11-03 | earnings call | scheduled | ir |
changes
| 2017-12-15 | Interim Principal Accounting Officer, appointed | sec_8k |
| 2017-02-24 | director, appointed | sec_8k |
| 2017-02-24 | director, departed | sec_8k |
| 2015-07-01 | director, appointed | sec_8k |
| 2014-11-24 | Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug rigel-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$